BCL2 and follicular lymphoma: For example, Batmanov et al. (2017) discovered regulatory mutations that control BCL2 and BCL6 expression in follicular lymphoma [14]; Arthur et al. (2018) identified aberrant expression of NFKBIZ in DLBCL caused by functional noncoding mutations in the 3’ untranslated region of the gene [15], and Puente et al. (2015) characterized enhancer mutations that deregulate PAX5 expression in CLL [8].